VXCO-100

Vaccine Company, Inc. · Phase 1 active Biologic

At a glance

Generic name	VXCO-100
Sponsor	Vaccine Company, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa (PHASE1)
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VXCO-100 CI brief — competitive landscape report
VXCO-100 updates RSS · CI watch RSS
Vaccine Company, Inc. portfolio CI